Findings

What do systematic reviews say?

266 questions · 274 findings · 25 reviews · Movement Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 13 · 4.7%GRADE not reported 7 · 2.6%Very low 66 · 24.1%Low 66 · 24.1%Moderate 87 · 31.8%High 35 · 12.8%

Botulinum toxin type A vs placebo

Subjective evaluation of the treatments by participants · adults with blepharospasm

1 finding from 1 review

Botulinum toxin type A therapy for blepharospasm 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High

Botulinum toxin type A vs placebo

Frequency of blepharospasm‐specific involuntary movements ( · adults with blepharospasm

1 finding from 1 review

Botulinum toxin type A therapy for blepharospasm 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Botulinum toxin type A vs placebo

Health‐related quality of life · adults with blepharospasm

The review found no eligible studies for this question.

1 finding from 1 review

Botulinum toxin type A therapy for blepharospasm 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Botulinum toxin type A vs placebo

Tolerability (number of dropouts; reported at any time) (2 RCT, 169 participants) · adults with blepharospasm

Botulinum toxin type A showed no clear difference in tolerability (number of dropouts; reported at any time) (2 RCT, 169… compared with placebo (moderate certainty).

1 finding from 1 review

Botulinum toxin type A therapy for blepharospasm 2020 · Cochrane Headline outcomes only
RR 1.44 [0.31, 6.79]
Studies not reported
Moderate

Botulinum toxin type A vs placebo

Duration of effect (when effects started to wane) · adults with blepharospasm

1 finding from 1 review

Botulinum toxin type A therapy for blepharospasm 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

GLP‐1 agonists vs placebo

PD motor impairment · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Low

GLP‐1 agonists vs placebo

Health‐related quality of life · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Low

GLP‐1 agonists vs placebo

Serious adverse events · adults with Parkinson's disease

The review found no eligible studies for this question.

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GLP‐1 agonists vs placebo

Adverse events ‐ weight loss · adults with Parkinson's disease

GLP‐1 receptor agonists showed no clear difference in adverse events ‐ weight loss compared with placebo (low certainty).

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
RR 1.25 [0.89, 1.76]
1 study · 60 participants
Low

GLP‐1 agonists vs no treatment

PD motor impairment · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

GLP‐1 agonists vs no treatment

Health‐related quality of life · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

GLP‐1 agonists vs no treatment

Serious adverse events. · adults with Parkinson's disease

It is very uncertain whether GLP‐1 receptor agonists changes serious adverse events. compared with no treatment (very low certainty).

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
RR 1.6 [0.4, 6.32]
1 study · 44 participants
Very low

GLP‐1 agonists vs no treatment

Adverse events ‐ weight loss · adults with Parkinson's disease

1 finding from 1 review

GLP‐1 receptor agonists for Parkinson's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

Summary of findings: Iron vs placebo

Change in IRLS severity scale score · patients with restless legs syndrome

1 finding from 1 review

Iron for the treatment of restless legs syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 345 participants
Moderate

Summary of findings: Iron vs placebo

Change in any measure of restlessness · patients with restless legs syndrome

1 finding from 1 review

Iron for the treatment of restless legs syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 370 participants
Moderate

Summary of findings: Iron vs placebo

Quality of life (dichotomous measure) · patients with restless legs syndrome

It is very uncertain whether iron changes quality of life (dichotomous measure) compared with placebo (very low certainty).

1 finding from 1 review

Iron for the treatment of restless legs syndrome 2019 · Cochrane Headline outcomes only
RR 2.01 [0.54, 7.45]
2 studies · 39 participants
Very low

Summary of findings: Iron vs placebo

Change in quality of life (continuous measure) · patients with restless legs syndrome

1 finding from 1 review

Iron for the treatment of restless legs syndrome 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 128 participants
Very low

Summary of findings: Iron vs placebo

Withdrew to use other RLS medication or because of inadequate RLS symptom control · patients with restless legs syndrome

Iron showed no clear difference in withdrew to use other RLS medication or because of inadequate RLS… compared with placebo (low certainty).

1 finding from 1 review

Iron for the treatment of restless legs syndrome 2019 · Cochrane Headline outcomes only
RR 0.77 [0.41, 1.47]
9 studies · 391 participants
Low

Summary of findings: Iron vs placebo

Adverse events · patients with restless legs syndrome

Iron showed no clear difference in adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Iron for the treatment of restless legs syndrome 2019 · Cochrane Headline outcomes only
RR 1.48 [0.97, 2.25]
6 studies · 298 participants
Moderate

Summary of findings: Iron vs placebo

Adverse effects (drop‐outs due to adverse effects4) · patients with restless legs syndrome

Iron showed no clear difference in drop out due to adverse event compared with placebo (low certainty).

1 finding from 1 review

Iron for the treatment of restless legs syndrome 2019 · Cochrane Headline outcomes only
RR 1.91 [0.5, 7.26]
9 studies · 398 participants
Low